Alanine-aminotransferase levels predict impaired glucose tolerance in a worksite population

Acta Diabetologica

Volumn 47, Issue 2, 2010, Pages 161-165

  Oberlinner, Christoph ^a   Zober, Andreas ^a   Nawroth, Peter P ^a   Humpert, Per M ^a   Morcos, Michael ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Alanine aminotransferase; Diabetes prediction; Diabetes risk; Screening; Worksite population

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLESTEROL; DIAGNOSTIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; EARLY INTERVENTION; EMPLOYEE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WORKPLACE; BLOOD; DIET RESTRICTION; EMPLOYMENT; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; REGRESSION ANALYSIS;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; EMPLOYMENT; FASTING; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 77952757799     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-009-0148-x     Document Type: Article

References (26)

1. Alberti KGM, Zimmet P, Shaw J (2005) The metabolic syndrome- a new worldwide definition. Lancet 366:1059-1062 (Pubitemid 41338752)
2. Ferrannini E (2007) Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 92:396-398
3. Funahashi T, Matsuzawa Y (2007) Metabolic syndrome: clinical concept and molecular basis. Ann Med 39:482-494
4. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197
5. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: report of the national heart, lung, and blood institute/american heart association conference on scientific issues related to definition. Circulation 109:433-438
6. Grundy SM (2007) Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92:399-404
7. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 112:2735-2752 (Pubitemid 41532612)
8. Godefroi R, Klementowicz P, Pepler C, Lewis B, McDonough K, Goldberg R (2005) Metabolic syndrome in a screened worksite sample: prevalence and predictors. Cardiology 103:131-136
9. Oberlinner C, Humpert P, Nawroth P, Zober A, Morcos M (2008) Metabolic syndrome in a large chemical company: prevalence in a screened worksite sample. Acta Diabetol 45:31-35
10. Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725-731
11. International Diabetes Prevention (IDF) (2005) The IDF consensus worldwide definition of the metabolic syndrome. IDF Communications. http://www.idf.org/webdata/docs/IDF-Meta- def-final.pdf. Accessed 2 Oct 2009
12. Knowler W, Barrett-Connor E, Fowler S, Amman R, Achin J, Walker E, Nathan D (2002) Diabetes prevention program research group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
13. The Diabetes Prevention Program Research Group (2002) The diabetes prevention program (DPP): description of lifestyle intervention. Diabetes Care 25:2165-2171
14. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB (2003) The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988-1994. Arch Intern Med 163:427-436 (Pubitemid 36241019)
15. Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J (2004) Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53:2855-2860
16. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS (2008) Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135:1935-1944
17. Olynyk JK, Knuiman MW, Divitini ML, Davis TM, Beilby J, Hung J (2009) Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol 104:1715-1722
18. Jo SK, Lee WY, Rhee EJ, Won JC, Jung CH, Park CY, Oh KW, Park SW, Kim SW (2009) Serum gamma-glutamyl transferase activity predicts future development of metabolic syndrome defined by two different criteria. Clin Chim Acta 403:234-240
19. Hertz RP, Unger AN, McDonald M, Lustik MB, Biddulph- Krentar J (2004) The impact of obesity on work limitations and cardiovascular risk factors in the US workforce. J Occup Environ Med 46:1196-1203
20. Persson U (1995) The indirect costs of morbidity in type II diabetic patients. Pharmacoeconomics 8(Suppl 1):28-32
21. Gesundheitsberichterstattung des Bundes (2006) Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes. http://www.gbe-bund.de/gbe10/owards. prc-show-pdf?p-id=9965 &p-sprache=D&p-uid=gast&p-aid=57637190&p- lfd-nr=1. Accessed 2 Oct 2009
22. Sabinsky MS, Toft U, Raben A, Holm L (2006) Overweight men's motivations and perceived barriers towards weight loss. Eur J Clin Nutr 61:526-531
23. Yeh MM, Brunt EM (2007) Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 128:837-847
24. Clark JM (2006) Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 40:S39-S43
25. Marchesini G, Natale S, Manini R, Agostini F (2005) Review article: the treatment of fatty liver disease associated with the metabolic syndrome. Aliment Pharmacol Ther 22(Suppl 2):37-39
26. Scheen AJ, Luyckx FH (2002) Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 16:703-716